KRAS and non-small cell lung carcinoma: In order to assess the prevalence of co-occurring KRAS mutations in NSCLC patients, we retrospectively analysed KRAS genotypes from a large cohort of patients screened for enrolment in the SELECT-1 Phase 3 study (NCT01933932), where mutant KRAS was a key eligibility criteria25.